View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps for Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice Changing Application

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Genentech, Incyte, Merck Sharp & Dohme Corp. and NantHealth, Inc.


Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Release Date: March 31, 2017
Expiration Date: March 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune checkpoint inhibitors in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapy.

CME/CE Activity Table of Contents

  • Module 1. A Patient With Platinum-Pretreated Bladder
  • Module 2: A Patient With Recurrent Head & Neck Cancer
  • Module 3. Metastatic Lung Cancer (squamous and nonsquamous)
  • Module 4. A Patient With Advanced, Previously Treated Melanoma
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the immunotherapies, and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer.
  • Evaluate clinical trial findings on immuno-oncology strategies and how they can be practically applied to the management of cancer in multiple lines of care.
  • Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies.
  • Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed.
  • Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies.

Faculty, Staff, and Planners' Disclosures

Faculty

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Disclosure: Consultant: Merck, Novartis, Roche; Shareholder: Abraxis, CytomX, Compugen, Five Prime, Kite Pharma

Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
New Haven, CT
 

Disclosure: Grant/Research Support: Oncogenix, Progenics, Johnson and Johnson, Millineum, Celgene, Dendreon, Sanofi, Agenysis, Eli Lilly, Roche Laboratories; Consultant: Bayer, Bellicum, Dendreon, Sanofi Avenitis, Johnson and Johnson, Exelixis, Ferring, Millineum, Medivation, Pfizer, Roche Laboratories, Tyme pharmaceuticals; Shareholder: Bellicum, Tyme

Tanguy Seiwert, MD
Medical Oncologist
The University of Chicago Medicine
Chicago, IL
 
 

Disclosure: Consultant: Amgen, Astra Zeneca, BMS, Celgene, Innate, Jounce, Lilly, Merck, Merck-Serono

Naiyer A Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosure: Consultant: Merck, Roche, BMS, AZ; Shareholder: Gritstone Oncology

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By